Relapsed data are uncompetitive, but the front-line PACC-mutant space offers hope.
ApexOnco Front Page
Recent articles
Though lung cancer looks promising a partner is now needed.
A single but durable stable disease sends the microcap's stock up 730%.
Data on J&J’s Tecvayli and Pfizer’s Elrexfio in relapsed multiple myeloma are due soon.
A newly published cache of CRLs includes six novel oncology drugs.
The deal for ISB 2001 is worth $700m up front.
Autogene cevumeran goes on hold in adjuvant bladder cancer.
Multispecifics newly into the clinic include Car-Ts from Essen and Unicar.
